Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2-Reference-Cited by-同舟云学术

Defining the optimal dose and therapeutic window in SMA with respiratory distress type I model mice, FVB/NJ-Ighmpb2

Published:2021-12 Issue: Volume:23 Page:23-32
ISSN:2329-0501
Container-title:Molecular Therapy - Methods & Clinical Development
language:en
Short-container-title:Molecular Therapy - Methods & Clinical Development

Author:

Shababi Monir,Smith Caley E.,Ricardez Hernandez Sara M.,Marquez Jose,Al Rawi Zayd,Villalón Eric,Farris K. David,Garro-Kacher Mona O.,Lorson Christian L.

Funder

National Institute of Neurological Disorders and Stroke

National Institutes of Health

NIGMS

Publisher

Elsevier BV

Subject

Genetics,Molecular Biology,Molecular Medicine

Reference31 articles.

1. Mutations in the gene encoding immunoglobulin mu-binding protein 2 cause spinal muscular atrophy with respiratory distress type 1;Grohmann;Nat. Genet.,2001

2. Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1);Grohmann;Ann. Neurol.,2003

3. Diaphragmatic spinal muscular atrophy with respiratory distress is heterogeneous, and one form Is linked to chromosome 11q13-q21;Grohmann;Am. J. Hum. Genet.,1999

4. Severe infantile neuropathy with diaphragmatic weakness and its relationship to SMARD1;Pitt;Brain,2003

5. Flexibility versus generalizability in model selection;Pitt;Psychon. Bull. Rev.,2003

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease Mechanisms and Therapeutic Approaches in SMARD1—Insights from Animal Models and Cell Models;Biomedicines;2024-04-11

2. The contribution and therapeutic implications of IGHMBP2 mutations on IGHMBP2 biochemical activity and ABT1 association;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-04

3. ABT1 modifies SMARD1 pathology via interactions with IGHMBP2 and stimulation of ATPase and helicase activity;JCI Insight;2023-01-24